Remarkable Result for Ambit and Astellas AML Drug

Final results of a Phase II study of quizartinib were presented at the American Society of Hematology meeting in Atlanta which suggest that drug could be a good option to treat patients with treatment-resistant acute myeloid leukaemia (AML). In the clinical study, the majority of participants carried a mutation in a gene called FLT3-ITD.  The

Continue Reading